메뉴 건너뛰기




Volumn 11, Issue 9, 2012, Pages 1978-1987

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib

Author keywords

[No Author keywords available]

Indexed keywords

DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TRASTUZUMAB;

EID: 84866133032     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0730     Document Type: Article
Times cited : (72)

References (43)
  • 3
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
    • (1987) Science , vol.235 , Issue.4785 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 10
    • 80052728749 scopus 로고    scopus 로고
    • Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint Analysis of Data from NCCTG N9831 and NSABP B-31
    • Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint Analysis of Data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73.
    • (2011) J Clin Oncol , vol.29 , pp. 3366-3373
    • Perez, E.A.1    Romond, E.H.2    Suman, V.J.3    Jeong, J.H.4    Davidson, N.E.5    Geyer Jr., C.E.6
  • 11
    • 76949095602 scopus 로고    scopus 로고
    • TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2/neu positive early breast cancer patients: BCIRG 006 study
    • abstract 62
    • TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2/neu positive early breast cancer patients: BCIRG 006 study (abstract 62). Cancer Res 2009;69.
    • (2009) Cancer Res , vol.69
    • Slamon, D.J.1    Eiermann, W.2    Robert, N.3
  • 14
    • 70449722853 scopus 로고    scopus 로고
    • Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions
    • Ocana A, Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev 2009;35:685-91.
    • (2009) Cancer Treat Rev , vol.35 , pp. 685-691
    • Ocana, A.1    Amir, E.2
  • 15
    • 73849107114 scopus 로고    scopus 로고
    • Neratinib: An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
    • Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 2009;18:1735-51.
    • (2009) Expert Opin Investig Drugs , vol.18 , pp. 1735-1751
    • Bose, P.1    Ozer, H.2
  • 16
    • 37549061078 scopus 로고    scopus 로고
    • PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32.
    • (2007) Cancer Res , vol.67 , pp. 11924-11932
    • Engelman, J.A.1    Zejnullahu, K.2    Gale, C.M.3    Lifshits, E.4    Gonzales, A.J.5    Shimamura, T.6
  • 17
    • 79952267022 scopus 로고    scopus 로고
    • Phase i dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors
    • Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17:1131-9.
    • (2011) Clin Cancer Res , vol.17 , pp. 1131-1139
    • Janne, P.A.1    Boss, D.S.2    Camidge, D.R.3    Britten, C.D.4    Engelman, J.A.5    Garon, E.B.6
  • 18
    • 51049123872 scopus 로고    scopus 로고
    • Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
    • Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008;7:1880-9.
    • (2008) Mol Cancer Ther , vol.7 , pp. 1880-1889
    • Gonzales, A.J.1    Hook, K.E.2    Althaus, I.W.3    Ellis, P.A.4    Trachet, E.5    Delaney, A.M.6
  • 19
    • 76049104235 scopus 로고    scopus 로고
    • PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    • Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
    • (2009) Breast Cancer Res , vol.11
    • Finn, R.S.1    Dering, J.2    Conklin, D.3    Kalous, O.4    Cohen, D.J.5    Desai, A.J.6
  • 20
    • 0036172653 scopus 로고    scopus 로고
    • Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction
    • DOI 10.1038/sj/leu/2402365
    • UphoffCC,DrexlerHG.Detectionof Mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction. Leukemia 2002;16:289-93. (Pubitemid 34145147)
    • (2002) Leukemia , vol.16 , Issue.2 , pp. 289-293
    • Uphoff, C.C.1    Drexler, H.G.2
  • 21
    • 0026937233 scopus 로고
    • Identifying individuals by sequencing mitochondrial DNA from teeth
    • Ginther C, Issel-Tarver L, King MC. Identifying individuals by sequencing mitochondrial DNA from teeth. Nature genetics 1992;2:135-8.
    • (1992) Nature Genetics , vol.2 , pp. 135-138
    • Ginther, C.1    Issel-Tarver, L.2    King, M.C.3
  • 22
    • 0029884715 scopus 로고    scopus 로고
    • Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
    • Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72. (Pubitemid 26248546)
    • (1996) Oncogene , vol.13 , Issue.1 , pp. 63-72
    • Pauletti, G.1    Godolphin, W.2    Press, M.F.3    Slamon, D.J.4
  • 23
    • 34548701082 scopus 로고    scopus 로고
    • Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro
    • Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-26.
    • (2007) Breast Cancer Res Treat , vol.105 , pp. 319-326
    • Finn, R.S.1    Dering, J.2    Ginther, C.3    Wilson, C.A.4    Glaspy, P.5    Tchekmedyian, N.6
  • 24
    • 77954572215 scopus 로고    scopus 로고
    • Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines
    • WilsonCADJ, Bernardo G, Rong HM, Ginther C, Ferdman R, Cook AM, et al. Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines. Breast Cancer Res 2005;7.
    • (2005) Breast Cancer Res , vol.7
    • Wilson, C.1    Bernardo, G.2    Rong, H.M.3    Ginther, C.4    Ferdman, R.5    Cook, A.M.6
  • 25
    • 77953411708 scopus 로고    scopus 로고
    • Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib
    • O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-502.
    • (2010) Mol Cancer Ther , vol.9 , pp. 1489-1502
    • O'Brien, N.A.1    Browne, B.C.2    Chow, L.3    Wang, Y.4    Ginther, C.5    Arboleda, J.6
  • 27
    • 33847147996 scopus 로고    scopus 로고
    • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
    • DOI 10.1007/s10549-006-9307-8
    • Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, et al. The combination of letrozole and trastuzumab as first or secondline biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9. (Pubitemid 46294957)
    • (2007) Breast Cancer Research and Treatment , vol.102 , Issue.1 , pp. 43-49
    • Marcom, P.K.1    Isaacs, C.2    Harris, L.3    Wong, Z.W.4    Kommarreddy, A.5    Novielli, N.6    Mann, G.7    Tao, Y.8    Ellis, M.J.9
  • 28
    • 57149096463 scopus 로고    scopus 로고
    • Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
    • Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52.
    • (2008) J Clin Oncol , vol.26 , pp. 5544-5552
    • Di Leo, A.1    Gomez, H.L.2    Aziz, Z.3    Zvirbule, Z.4    Bines, J.5    Arbushites, M.C.6
  • 29
    • 73149115341 scopus 로고    scopus 로고
    • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    • Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
    • (2009) J Clin Oncol , vol.27 , pp. 5538-5546
    • Johnston, S.1    Pippen Jr., J.2    Pivot, X.3    Lichinitser, M.4    Sadeghi, S.5    Dieras, V.6
  • 30
    • 59449106972 scopus 로고    scopus 로고
    • HER-2 gene ampli fication, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy inwomen with metastatic breast cancer
    • Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, et al. HER-2 gene ampli fication, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy inwomen with metastatic breast cancer. Clin Cancer Res 2008;14:7861-70.
    • (2008) Clin Cancer Res , vol.14 , pp. 7861-7870
    • Press, M.F.1    Finn, R.S.2    Cameron, D.3    Di Leo, A.4    Geyer, C.E.5    Villalobos, I.E.6
  • 31
    • 48649092620 scopus 로고    scopus 로고
    • A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy
    • Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-87.
    • (2008) Cancer Res , vol.68 , pp. 5878-5887
    • Lee-Hoeflich, S.T.1    Crocker, L.2    Yao, E.3    Pham, T.4    Munroe, X.5    Hoeflich, K.P.6
  • 32
    • 0035915421 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor signaling and resistance to transtuzumab (Herceptin)
    • Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7. (Pubitemid 34048651)
    • (2001) Journal of the National Cancer Institute , vol.93 , Issue.24 , pp. 1852-1857
    • Lu, Y.1    Zi, X.2    Zhao, Y.3    Mascarenhas, D.4    Pollak, M.5
  • 33
    • 0036606779 scopus 로고    scopus 로고
    • The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides
    • Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62: 3151-8. (Pubitemid 34602408)
    • (2002) Cancer Research , vol.62 , Issue.11 , pp. 3151-3158
    • Motoyama, A.B.1    Hynes, N.E.2    Lane, H.A.3
  • 34
    • 28244432561 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
    • DOI 10.1158/0008-5472.CAN-04-3841
    • Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28. (Pubitemid 41713383)
    • (2005) Cancer Research , vol.65 , Issue.23 , pp. 11118-11128
    • Nahta, R.1    Yuan, L.X.H.2    Zhang, B.3    Kobayashi, R.4    Esteva, F.J.5
  • 35
    • 34548071359 scopus 로고    scopus 로고
    • Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
    • DOI 10.1158/1078-0432.CCR-07-0701
    • RitterCA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al.Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13:4909-19. (Pubitemid 47294799)
    • (2007) Clinical Cancer Research , vol.13 , Issue.16 , pp. 4909-4919
    • Ritter, C.A.1    Perez-Torres, M.2    Rinehart, C.3    Guix, M.4    Dugger, T.5    Engelman, J.A.6    Arteaga, C.L.7
  • 37
    • 65349101151 scopus 로고    scopus 로고
    • Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
    • Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-40.
    • (2009) Cancer Cell , vol.15 , pp. 429-440
    • Junttila, T.T.1    Akita, R.W.2    Parsons, K.3    Fields, C.4    Lewis Phillips, G.D.5    Friedman, L.S.6
  • 39
    • 9244219598 scopus 로고    scopus 로고
    • Breast cancer - Loss of PTEN predicts resistance to treatment
    • DOI 10.1056/NEJMcibr043143
    • PandolfiPP. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 2004;351:2337-8. (Pubitemid 39552753)
    • (2004) New England Journal of Medicine , vol.351 , Issue.22 , pp. 2337-2338
    • Pandolfi, P.P.1
  • 40
    • 78650487946 scopus 로고    scopus 로고
    • HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer
    • Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 2010;8: e1000563.
    • (2010) PLoS Biol , vol.8
    • Gijsen, M.1    King, P.2    Perera, T.3    Parker, P.J.4    Harris, A.L.5    Larijani, B.6
  • 42
    • 33646746413 scopus 로고    scopus 로고
    • A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
    • Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006;103:7795-800.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 7795-7800
    • Xia, W.1    Bacus, S.2    Hegde, P.3    Husain, I.4    Strum, J.5    Liu, L.6
  • 43
    • 70149109569 scopus 로고    scopus 로고
    • Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL
    • Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8.
    • (2009) Cancer Res , vol.69 , pp. 6871-6878
    • Liu, L.1    Greger, J.2    Shi, H.3    Liu, Y.4    Greshock, J.5    Annan, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.